Crossmark

Safety, pharmacokinetic and pharmacodynamic properties of single ascending dose and continuous infusion of remimazolam besylate in healthy Chinese volunteers

Crossref DOI link: https://doi.org/10.1007/s00228-019-02800-3

Published Online: 2019-12-23

Published Print: 2020-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sheng, Xiao-yan

Liang, Yan

Yang, Xue-yuan

Li, Li-e

Ye, Xia

Zhao, Xia

Cui, Yi-min https://orcid.org/0000-0002-4186-1005
License Information

Text and Data Mining valid from 2019-12-23

Version of Record valid from 2019-12-23
More Information

Article History

Received: 7 August 2019

Accepted: 18 November 2019

First Online: 23 December 2019

Compliance with ethical standards

:

: Li-e Li and Xia Ye are employees of Yichang Humanwell Pharmaceutical Co., Ltd., which sponsored the clinical trial. The other authors have no conflicts of interest.

Document is current

Any future updates will be listed below